Metabolic therapy with Sodium R lipoate plus hydroxycitrate - Revision history

Lazy at 08:18, 18 January 2025

2025-01-18T08:18:49Z

← Older revision		Revision as of 01:18, 18 January 2025
Line 13:		Line 13:
	\|toxicity_level=2		\|toxicity_level=2
	\|toxicity_explanation=The toxicity of Sodium R Lipoate and Hydroxycitrate (METABLOC) has been assessed as relatively low. It's still undergoing early clinical evaluation, which means it hasn't caused any severe adverse reactions to this point. However, we lack specific information on its common side effects. It's important to remember that everybody's body responds differently to medications, so while the toxicity appears low, some individuals may still experience side effects.		\|toxicity_explanation=The toxicity of Sodium R Lipoate and Hydroxycitrate (METABLOC) has been assessed as relatively low. It's still undergoing early clinical evaluation, which means it hasn't caused any severe adverse reactions to this point. However, we lack specific information on its common side effects. It's important to remember that everybody's body responds differently to medications, so while the toxicity appears low, some individuals may still experience side effects.
	}}		\|overview=Sodium R Lipoate and Hydroxycitrate (METABLOC) is an investigational metabolic therapy for brain tumors, particularly gliomas, showing promising outcomes in early clinical evaluations, including significant tumor shrinkage and extended progression-free survival in some patients. While the therapy has a relatively low toxicity level and no severe adverse reactions reported thus far, further large-scale trials are needed to confirm its efficacy and safety.}}

69.163.248.232: Updated category= to treatment_category= in TreatmentInfo template

2024-11-12T18:27:31Z

Updated category= to treatment_category= in TreatmentInfo template

← Older revision		Revision as of 11:27, 12 November 2024
Line 9:		Line 9:
	\|usefulness_rating=3		\|usefulness_rating=3
	\|notes=This metabolic therapy, combining sodium R lipoate and hydroxycitrate, has shown promising outcomes in a small French study involving glioma patients. The therapy aims to disrupt cancer metabolism, potentially extending survival and reducing tumor size in some patients. While preliminary results are encouraging, particularly for patients with newly diagnosed gliomas, the need for well-conducted, larger-scale trials is emphasized to firmly establish efficacy and safety.		\|notes=This metabolic therapy, combining sodium R lipoate and hydroxycitrate, has shown promising outcomes in a small French study involving glioma patients. The therapy aims to disrupt cancer metabolism, potentially extending survival and reducing tumor size in some patients. While preliminary results are encouraging, particularly for patients with newly diagnosed gliomas, the need for well-conducted, larger-scale trials is emphasized to firmly establish efficacy and safety.
	\|~~category~~=Over-the-Counter Drugs and Supplements		\|treatment_category=Over-the-Counter Drugs and Supplements
	\|links=		\|links=
	\|toxicity_level=2		\|toxicity_level=2
	\|toxicity_explanation=The toxicity of Sodium R Lipoate and Hydroxycitrate (METABLOC) has been assessed as relatively low. It's still undergoing early clinical evaluation, which means it hasn't caused any severe adverse reactions to this point. However, we lack specific information on its common side effects. It's important to remember that everybody's body responds differently to medications, so while the toxicity appears low, some individuals may still experience side effects.		\|toxicity_explanation=The toxicity of Sodium R Lipoate and Hydroxycitrate (METABLOC) has been assessed as relatively low. It's still undergoing early clinical evaluation, which means it hasn't caused any severe adverse reactions to this point. However, we lack specific information on its common side effects. It's important to remember that everybody's body responds differently to medications, so while the toxicity appears low, some individuals may still experience side effects.
	}}		}}

Lazy at 16:54, 27 March 2024

2024-03-27T16:54:04Z

← Older revision		Revision as of 09:54, 27 March 2024
Line 11:		Line 11:
	\|category=Over-the-Counter Drugs and Supplements		\|category=Over-the-Counter Drugs and Supplements
	\|links=		\|links=
			\|toxicity_level=2
			\|toxicity_explanation=The toxicity of Sodium R Lipoate and Hydroxycitrate (METABLOC) has been assessed as relatively low. It's still undergoing early clinical evaluation, which means it hasn't caused any severe adverse reactions to this point. However, we lack specific information on its common side effects. It's important to remember that everybody's body responds differently to medications, so while the toxicity appears low, some individuals may still experience side effects.
	}}		}}

Lazy: Created page with "{{TreatmentInfo |drug_name=Sodium R Lipoate and Hydroxycitrate (METABLOC) |FDA_approval=No (Used in investigational metabolic therapy for brain tumors) |used_for=Investigational use in brain tumor treatment, including primary and metastatic gliomas |clinical_trial_phase=Early clinical evaluation in a small case series |common_side_effects=Not specified in the provided information |OS_with=Varies; one GBM patient had a significant tumor shrinkage, others showed extended p..."

2024-03-21T12:05:07Z

Created page with "{{TreatmentInfo |drug_name=Sodium R Lipoate and Hydroxycitrate (METABLOC) |FDA_approval=No (Used in investigational metabolic therapy for brain tumors) |used_for=Investigational use in brain tumor treatment, including primary and metastatic gliomas |clinical_trial_phase=Early clinical evaluation in a small case series |common_side_effects=Not specified in the provided information |OS_with=Varies; one GBM patient had a significant tumor shrinkage, others showed extended p..."

New page

{{TreatmentInfo
|drug_name=Sodium R Lipoate and Hydroxycitrate (METABLOC)
|FDA_approval=No (Used in investigational metabolic therapy for brain tumors)
|used_for=Investigational use in brain tumor treatment, including primary and metastatic gliomas
|clinical_trial_phase=Early clinical evaluation in a small case series
|common_side_effects=Not specified in the provided information
|OS_with=Varies; one GBM patient had a significant tumor shrinkage, others showed extended progression-free survival, including one patient surviving 87 months post-diagnosis
|PFS_with=Majority of newly diagnosed patients without disease progression for periods extending to 2-3 years, and in one case, 87 months
|usefulness_rating=3
|notes=This metabolic therapy, combining sodium R lipoate and hydroxycitrate, has shown promising outcomes in a small French study involving glioma patients. The therapy aims to disrupt cancer metabolism, potentially extending survival and reducing tumor size in some patients. While preliminary results are encouraging, particularly for patients with newly diagnosed gliomas, the need for well-conducted, larger-scale trials is emphasized to firmly establish efficacy and safety.
|category=Over-the-Counter Drugs and Supplements
|links=
}}